Drugs / 68Ga-NOTA-GPA33 nanobody
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07172503 | Oct 2025 → Sep 2026 overdue | colorectal cancer, gastric cancer, malignant pancreatic neoplasm | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NOTA-GPA33 nanobody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07172503 ↗ |
| Modality | Protein / enzyme biologic | “68Ga-NOTA-GPA33 nanobody” NCT07172503 ↗ |
| Target | GPA33 | “targeting GPA33” NCT07172503 ↗ |